Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568458 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT06568458 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 71 participants.
The verdict
NCT06568458, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants
Interventions
- DRUG Nintedanib
- DRUG BMS 986278
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568458
The ClinicalTrials.gov registry entry for NCT06568458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nintedanib is the first listed.
NCT06568458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06568458 about?
NCT06568458 is a clinical study titled "A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants". The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants
What is the current status of trial NCT06568458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2024-09-19. Estimated completion is 2025-02-27.
What interventions are being tested in trial NCT06568458?
The interventions under investigation include: Nintedanib (DRUG), BMS 986278 (DRUG).
Who is sponsoring clinical trial NCT06568458?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.